Subunit and Recombinant Vaccines

A subunit vaccine contains only selected, purified components of a pathogen — typically one or a few proteins or polysaccharides — rather than the whole organism, and recombinant vaccines produce those antigens in engineered cells (bacteria, yeast, insect or mammalian cells) using recombinant DNA technology. By presenting a well-defined antigen with no infectious material, this platform is very safe and precisely characterized, but the purified antigen is often weakly immunogenic on its own and usually requires an adjuvant to generate a strong, protective response.

Definition

A subunit or recombinant vaccine is a preparation containing only defined, purified antigenic components of a pathogen — produced synthetically, by purification, or via recombinant expression — formulated, often with an adjuvant, to elicit protective immunity without any infectious agent.

Scope

This topic covers how protective antigens are chosen and produced (including virus-like particles, conjugate, and genome-guided reverse-vaccinology approaches), why purified antigens generally need adjuvants, and the trade-offs of the platform. It is a methodological reference and does not provide immunization schedules or eligibility advice.

Core questions

• How is a protective antigen identified and produced recombinantly?
• Why do purified subunit antigens usually require adjuvants?
• How do conjugate, virus-like-particle, and reverse-vaccinology strategies extend the platform?

Key concepts

• Purified protein or polysaccharide antigen
• Recombinant expression systems
• Virus-like particles (VLPs)
• Polysaccharide-protein conjugation
• Adjuvant requirement
• Reverse vaccinology (genome-guided antigen discovery)
• High safety and antigen definition

Mechanisms

By delivering only chosen antigens, subunit vaccines focus the immune response on protective epitopes while excluding components that might cause reactogenicity or are irrelevant to protection. Because these purified antigens lack the danger signals of a whole pathogen, they are often poorly immunogenic alone and are formulated with adjuvants that activate innate immune sensing to amplify and shape the adaptive response. Several engineering strategies enhance the platform: assembling antigens into virus-like particles that mimic viral surface geometry, chemically conjugating poorly immunogenic polysaccharides to carrier proteins to recruit T-cell help, and using genome sequencing to identify candidate antigens that cannot be grown conventionally — the reverse-vaccinology approach pioneered against serogroup B meningococcus by Pizza and colleagues.

Clinical relevance

Subunit and recombinant vaccines offer a highly defined, well-tolerated platform that has enabled vaccines against pathogens difficult to address by whole-organism approaches. Understanding the platform explains why such vaccines are precisely characterized and safe yet typically depend on adjuvants for potency. This entry describes the science of the platform and is not a source of individual vaccination advice.

Epidemiology

Recombinant and subunit vaccines, including conjugate and virus-like-particle products, have contributed substantially to the control of several bacterial and viral diseases and represent a major share of modern licensed vaccines, reflecting the platform's safety and manufacturability.

History

The platform emerged with recombinant DNA technology in the late twentieth century, which allowed protective antigens to be produced in engineered cells rather than purified from the pathogen. Genome sequencing then enabled reverse vaccinology — mining the full genome for candidate antigens — first demonstrated against serogroup B meningococcus in 2000, extending the reach of subunit design to previously intractable targets.

Key figures

• Rino Rappuoli
• Bali Pulendran
• Stanley Plotkin

Seminal works

• pizza-2000
• plotkin-2010

Frequently asked questions

Why do subunit vaccines usually contain an adjuvant?

Purified antigens lack the innate-immune danger signals of a whole pathogen, so they are often weakly immunogenic on their own; an adjuvant activates innate sensing to boost and shape the adaptive response toward protective immunity.

What is reverse vaccinology?

It is a genome-guided strategy in which a pathogen's full DNA sequence is screened computationally to identify candidate protein antigens, which are then produced recombinantly and tested — first applied successfully to serogroup B meningococcus, a target that resisted conventional approaches.